Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT02351739 |
| Title | Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Platinum-refractory Metastatic Bladder Cancer |
| Acronym | KEYNOTE143 |
| Recruitment | Completed |
| Gender | both |
| Phase | Phase II |
| Variant Requirements | No |
| Sponsors | Acerta Pharma BV |
| Indications | |
| Therapies | |
| Age Groups: | adult |
| Covered Countries | USA |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| University of Chicago | Chicago | Illinois | United States | Details | ||
| University of Michigan | Ann Arbor | Michigan | United States | Details | ||
| Durham | North Carolina | United States | Details | |||
| James Cancer Hospital | Columbus | Ohio | United States | Details | ||
| Oregon Health and Science University | Portland | Oregon | United States | Details | ||
| University of Pittsburgh | Pittsburgh | Pennsylvania | United States | Details | ||
| Carolina Urologic Research Center | Myrtle Beach | South Carolina | United States | Details |